Compare JHG & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JHG | ICLR |
|---|---|---|
| Founded | 1934 | 1990 |
| Country | United Kingdom | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 8.2B |
| IPO Year | 2003 | 2001 |
| Metric | JHG | ICLR |
|---|---|---|
| Price | $51.59 | $115.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $48.29 | ★ $178.62 |
| AVG Volume (30 Days) | ★ 3.3M | 766.1K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 104.30 | N/A |
| EPS | ★ 5.23 | N/A |
| Revenue | ★ $1,743,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.49 | N/A |
| P/E Ratio | ★ $9.86 | $12.91 |
| Revenue Growth | ★ 74.39 | N/A |
| 52 Week Low | $29.29 | $66.57 |
| 52 Week High | $53.76 | $211.00 |
| Indicator | JHG | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 57.54 |
| Support Level | $50.02 | $102.53 |
| Resistance Level | $51.75 | $155.58 |
| Average True Range (ATR) | 0.12 | 4.98 |
| MACD | -0.05 | 1.85 |
| Stochastic Oscillator | 58.54 | 79.26 |
Janus Henderson Group provides investment management services to retail intermediary (50% of managed assets), self-directed (20%) and institutional (30%) clients. At the end of September 2025, active equities (52%), fixed-income (32%), balanced (12%) and alternative (4%) investment platforms constituted the company's $484 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (67%), with customers from Europe, the Middle East, Africa, and Latin America (25%) and the Asia-Pacific region (8%) accounting for the remainder.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.